Beam Therapeutics (BEAM) fell more than 5% in recent trading Tuesday after reporting a wider Q1 loss from the same period a year earlier.
The company reported a Q1 net loss of $1.24 per share, widening from a loss of $1.21 a year earlier.
Analysts polled by FactSet expected a loss of $1.18.
License and collaboration revenue for the quarter ended March 31 was $7.5 million, up from $7.4 million a year earlier.
Analysts surveyed by FactSet expected $14 million.
The company said it had cash, cash equivalents and marketable securities of $1.22 billion as of March 31 to finance its expected operating expenses and capital expenditure requirements into 2028.
Price: 18.75, Change: -1.07, Percent Change: -5.40
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.